Search

Your search keyword '"O'CALLAGHAN, C. J."' showing total 184 results

Search Constraints

Start Over You searched for: Author "O'CALLAGHAN, C. J." Remove constraint Author: "O'CALLAGHAN, C. J."
184 results on '"O'CALLAGHAN, C. J."'

Search Results

1. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database

17. A PHASE III RANDOMIZED CONTROLLED TRIAL OF SHORT-COURSE RADIOTHERAPY WITH OR WITHOUT CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677)

18. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

19. Autosomal dominant vasovagal syncope: Clinical features and linkage to chromosome 15q26

20. Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.

21. Diurnal blood pressure and urine production in acute spinal cord injury compared with controls

22. A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).

23. The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.

24. The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.

25. A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

26. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013.

27. The relationship between the development of rash and clinical and quality of life outcomes by Kras mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.

28. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.

30. High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17—A phase III trial of cetuximab versus best supportive care (BSC)

31. Role of Migratory Birds in Introduction and Range Expansion of Ixodes scapularis Ticks and of Borrelia burgdorferi and Anaplasma phagocytophilum in Canada

34. A retrospective review of the ambulatory blood pressure patterns and diurnal urine production in subgroups of spinal cord injured patients.

35. Intestinal parasites in swine in the the Nordic countries:multilevel modelling of Ascaris suum infections in relation to production factors

39. Investigation of Ground Level and Remote-Sensed Data for Habitat Classification and Prediction of Survival of Ixodes scapularis in Habitats of Southeastern Canada

40. Investigation of Ground Level and Remote-Sensed Data for Habitat Classification and Prediction of Survival ofIxodes scapularisin Habitats of Southeastern Canada

44. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

Catalog

Books, media, physical & digital resources